These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28678537)

  • 21. Pharmacological treatment for uterine leiomyosarcomas.
    Gadducci A; Guerrieri ME
    Expert Opin Pharmacother; 2015 Feb; 16(3):335-46. PubMed ID: 25418060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions
    Paludetto MN; Stigliani JL; Robert A; Bernardes-Génisson V; Chatelut E; Puisset F; Arellano C
    Chem Res Toxicol; 2020 Jan; 33(1):181-190. PubMed ID: 31535851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of pazopanib administered in combination with bevacizumab.
    Imbs DC; Négrier S; Cassier P; Hollebecque A; Varga A; Blanc E; Lafont T; Escudier B; Soria JC; Pérol D; Chatelut E
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1189-96. PubMed ID: 24705975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels.
    Groenland SL; Katz D; Huitema ADR; Steeghs N
    BMC Cancer; 2018 Dec; 18(1):1200. PubMed ID: 30509247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic effects of pazopanib and hyperthermia against uterine leiomyosarcoma growth mediated by downregulation of histone acetyltransferase 1.
    Lin CY; Chao A; Wu RC; Lee LY; Ueng SH; Tsai CL; Lee YS; Peng MT; Yang LY; Huang HJ; Wang HS; Lai CH
    J Mol Med (Berl); 2020 Aug; 98(8):1175-1188. PubMed ID: 32638047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
    Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
    Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.
    Deng Y; Sychterz C; Suttle AB; Dar MM; Bershas D; Negash K; Qian Y; Chen EP; Gorycki PD; Ho MY
    Xenobiotica; 2013 May; 43(5):443-53. PubMed ID: 23548165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pazopanib and soft-tissue sarcomas. Too toxic.
    Prescrire Int; 2013 Jun; 22(139):145-7. PubMed ID: 23866345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pazopanib: in advanced soft tissue sarcoma.
    Deeks ED
    Drugs; 2012 Nov; 72(16):2129-40. PubMed ID: 23072642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
    Chamberlain FE; Wilding C; Jones RL; Huang P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):505-511. PubMed ID: 31010343
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
    Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
    BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
    Reardon DA; Groves MD; Wen PY; Nabors L; Mikkelsen T; Rosenfeld S; Raizer J; Barriuso J; McLendon RE; Suttle AB; Ma B; Curtis CM; Dar MM; de Bono J
    Clin Cancer Res; 2013 Feb; 19(4):900-8. PubMed ID: 23363814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
    Wilding CP; Elms ML; Judson I; Tan AC; Jones RL; Huang PH
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):971-991. PubMed ID: 31665941
    [No Abstract]   [Full Text] [Related]  

  • 35. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature.
    Fanelli M; Caputo F; Cerma K; Gelsomino F; Bari A; Dominici M; Pozzi S
    J Oncol Pharm Pract; 2021 Apr; 27(3):766-770. PubMed ID: 32838682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
    Heath EI; Chiorean EG; Sweeney CJ; Hodge JP; Lager JJ; Forman K; Malburg L; Arumugham T; Dar MM; Suttle AB; Gainer SD; LoRusso P
    Clin Pharmacol Ther; 2010 Dec; 88(6):818-23. PubMed ID: 20980999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
    Kitamura S; Yanagi T; Inamura Y; Hata H; Imafuku K; Yoshino K; Shimizu H
    J Dermatol; 2017 Jan; 44(1):64-67. PubMed ID: 27569550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
    Kasper B; Hohenberger P
    Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.
    Karaağaç M; Eryılmaz MK
    J Oncol Pharm Pract; 2020 Apr; 26(3):768-774. PubMed ID: 31547750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.